{
  "id": "61f6055b882a024a10000021",
  "type": "list",
  "question": "Which receptors are targeted by Tirzepatide?",
  "ideal_answer": "Tirzepatide is dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34542221",
    "http://www.ncbi.nlm.nih.gov/pubmed/32291277",
    "http://www.ncbi.nlm.nih.gov/pubmed/32519795",
    "http://www.ncbi.nlm.nih.gov/pubmed/33236115",
    "http://www.ncbi.nlm.nih.gov/pubmed/34431633",
    "http://www.ncbi.nlm.nih.gov/pubmed/34626443",
    "http://www.ncbi.nlm.nih.gov/pubmed/34518444",
    "http://www.ncbi.nlm.nih.gov/pubmed/34003802",
    "http://www.ncbi.nlm.nih.gov/pubmed/33778934",
    "http://www.ncbi.nlm.nih.gov/pubmed/34819089",
    "http://www.ncbi.nlm.nih.gov/pubmed/34608929",
    "http://www.ncbi.nlm.nih.gov/pubmed/34370970",
    "http://www.ncbi.nlm.nih.gov/pubmed/34170647",
    "http://www.ncbi.nlm.nih.gov/pubmed/32730231",
    "http://www.ncbi.nlm.nih.gov/pubmed/33325008",
    "http://www.ncbi.nlm.nih.gov/pubmed/33030356",
    "http://www.ncbi.nlm.nih.gov/pubmed/34681215"
  ],
  "snippets": [
    {
      "text": "The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34542221",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15\u2009mg), dulaglutide (1.5\u2009mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34542221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirzepatide, a glucose-insulin peptide and GLP-1 dual agonist is in phase 3 study for obesity management, and bimagrumab is a new agent in phase 2 with a unique mechanism of action; they are generating much interest. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34518444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects with Type 2 Diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34608929",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34819089",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In this framework, the novel dual GIP and GLP-1 receptor agonist tirzepatide seems to be not just a new antidiabetic medication. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34819089",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirzepatide and additional dual GLP-1/GIP receptor agonists that could eventually be developed in the future seem to be a promising furthest advance for the management of several cardiometabolic settings. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34819089",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type\u00a02 Diabetes: The SURPASS Clinical Trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33325008",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Tirzepatide is a novel dual GIP/GLP-1 receptor agonist formulated as a synthetic peptide containing 39\u00a0amino acids, based on the native GIP sequence.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33325008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33236115",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONTEXT: Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33236115",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, the mechanism by which tirzepatide improves efficacy and how GIP receptor (GIPR) agonism contributes is not fully understood.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34003802",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730231",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32519795",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730231",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirzepatide is a dual gastric inhibitory peptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist formulated as a synthetic linear peptide, based on the native GIP sequence.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626443",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626443",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The effect of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide on gastric emptying (GE) was compared to that of GLP-1RAs in non-clinical and clinical studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32519795",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Three approaches may be considered to potentiate weight loss: an increase of the drug dosage because of the demonstration of a dose-response, an add-on therapy with a sodium-glucose cotransporter type 2 inhibitor as this agent exerts a complementary action through urinary calorie loss (glucosuria) or a combination of the effects of two incretin hormones (GLP-1 and GIP), as the potent dual agonist tirzepatide currently in development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431633",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Early phase trials in T2DM indicate that tirzepatide improves clinical outcomes beyond those achieved by a selective GLP-1 receptor agonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730231",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34170647",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirzepatide is a novel once-a-week dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, currently under trial to assess glycemic efficacy and safety in people with type 2 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34681215",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34170647",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "k, the novel dual GIP and GLP-1 receptor agonist tirzepatide seems to be not just a new antidiabetic medication. Administered as",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34819089",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes melli",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291277",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pharmacologically, signaling studies demonstrate that tirzepatide mimics the actions of native GIP at the GIP receptor but shows bias at the GLP-1 receptor to favor cAMP generation over \u03b2-arrestin recruitment, coincident with a weaker ability to drive GLP-1 receptor internalization compared with GLP-1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730231",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND AIMS: The pharmacokinetics (PK) and single-dose tolerability of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist being developed for once-weekly treatment of type 2 diabetes (T2D), weight management, and nonalcoholic steatohepatitis, was evaluated in subjects with renal impairment versus healthy subjects with n",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33778934",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nts with T2D.AREAS COVERED: Tirzepatide is an unimolecular dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA in developme",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33030356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes mellitus (T2DM)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291277",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirzepatide (LY3298176), a dual GIP and GLP-1 receptor (GLP-1R) agonist, delivered superior glycemic control and weight loss compared with GLP-1R agonism in patients with type 2 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34003802",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34170647",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this framework, the novel dual GIP and GLP-1 receptor agonist tirzepatide seems to be not just a new antidiabetic medication.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34819089",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This analysis reveals a greater degree of engagement of tirzepatide for the GIP receptor than the GLP-1 receptor, corroborating an imbalanced mechanism of action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730231",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for the treatment of type",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34370970",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Experiments in primary islets reveal \u03b2-arrestin1 limits the insulin response to GLP-1, but not GIP or tirzepatide, suggesting that the biased agonism of tirzepatide enhances insulin secretion.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730231",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1"
}